Drug intelligence / Profile preview

oxybutynin + antibiotics

Development stage
Unknown
Lead developer
University of Calgary
Modality
Small Molecules
Administration
Oral
01

Overview

The combination of oxybutynin and standard antimicrobial (antibiotic) therapy is an adjunctive treatment strategy investigated for the management of pediatric cystitis. Oxybutynin is a small molecule anticholinergic agent that acts as a bladder antispasmodic by antagonizing muscarinic receptors in the bladder wall, thereby reducing detrusor muscle spasms and associated symptoms such as pain, urgency, and frequency. In this therapeutic approach, oxybutynin is administered alongside standard-of-care antibiotics to address both the underlying bacterial infection and the symptomatic bladder irritation. This specific combination was the subject of a randomized, double-blind, placebo-controlled clinical trial conducted by the University of Calgary, which evaluated the efficacy of oral oxybutynin syrup in reducing pain and discomfort in children aged 4 to 16 years with acute cystitis.

Other names
antibiotics-University of Calgary-cystitisoxybutynin as adjunctive therapy to standard antimicrobial treatmentoxybutynin + antimicrobial therapy
02

Targets

CHRM3 (M3)CHRM2 (M2)M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on oxybutynin + antibiotics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on oxybutynin + antibiotics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call